The FDA approved dupilumab to treat children aged 2 to 11 years with chronic spontaneous urticaria and persistent symptoms ...

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s ...

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe ...

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

Sanofi SNY and its partner Regeneron Pharmaceuticals REGN announced that the FDA has approved the expanded use of their ...

Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. | In ...

By Bhanvi Satija and Mariam Sunny LONDON, April 23 (Reuters) - French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...